1-3 of 3
Silvana Lalo, MBA
Close
Sort by
Journal Articles

Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical Trial

Suzanne Lentzsch, MD, PhD, Amy O'Sullivan, RN, BSN, Ryan Kennedy, BS, Navkiranjit Gill, DO, Carrie Andreas, PA-C, Diane Gardner, MSN, CRNP, BC, Silvana Lalo, MBA, Steve Burt, NP, Robert L. Redner, MD, Robert Volkin, MD, David Roodman, MD, PhD, Markus Y Mapara, MD, PhD, Frank Viverette, MD, Mounzer Agha, MD, Jeffrey A. Zonder, MD
Journal: Blood
Blood (2010) 116 (21): 989.
https://doi.org/10.1182/blood.V116.21.989.989
Published: 2010
Journal Articles

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.

Jeffrey A Zonder, MD, Vaishali Sanchorawala, MD, Rachel M. Snyder, PhD, Jeffrey Matous, MD, Howard Terebelo, MD, Nalini Janakiraman, MD, Markus Y Mapara, MD, PhD, Silvana Lalo, MBA, Nishant Tageja, MD, Craig Webb, PhD, David Monsma, PhD, Catherine Sellers, RN, Judith Abrams, Statistician, Cristina Gasparetto, MD
Journal: Blood
Blood (2009) 114 (22): 746.
https://doi.org/10.1182/blood.V114.22.746.746
Published: 2009
Journal Articles

A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma.

Suzanne Lentzsch, MD, PhD, Amy O’Sullivan, RN, BSN, Silvana Lalo, MBA, Carrie Kruppa, MPAS, PA-C, Diane Gardner, RN, CRNP, Ryan C Kennedy, BS, Steve Burt, NP, Markus Y Mapara, MD, PhD, Robert Redner, MD, David Roodman, MD, PhD, Robert L Volkin, MD, Jeffrey Zonder, MD
Journal: Blood
Blood (2009) 114 (22): 1856.
https://doi.org/10.1182/blood.V114.22.1856.1856
Published: 2009